GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece,
Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.
.
( Total: 48 Current Stock Recommendations )
Gilead Sciences, Inc.   (48)
Sell Hold 15% Buy 81%
Related companies
Sanofi-aventis Sa   (17)
Hold 47% Buy 53%
Allergan, Inc.   (30)
Hold 40% Buy 60%
Novo Nordisk A/s   (18)
Sell 17% Hold 44% Buy 39%
Amgen Inc.   (30)
Hold 47% Buy 53%
Teva Pharmaceutical ...   (41)
Hold 27% Buy 73%
Celgene Corporation   (44)
Sell Hold Buy 84%
Allergan Plc   (28)
Hold 29% Buy 71%
Biogen Idec Inc   (41)
Sell Hold 27% Buy 68%
Filter by Gains:   
  
Rating:
Buy GILD
up 309.98 %

Rating:
Buy GILD
up 330.06 %

Rating:
Buy GILD
up 109.93 %

Rating:
Buy GILD
up 453.22 %

Rating:
Buy GILD
up 109.93 %

Rating:
Buy GILD
up 8.54 %

Rating:
Buy GILD
up 396.84 %

Rating:
Buy GILD
up 8.54 %

Rating:
Buy GILD
up 177.68 %

Rating:
Buy GILD
up 109.93 %

Rating:
Buy GILD
up 309.98 %

Rating:
Buy GILD
up 396.84 %

Rating:
Buy GILD
up 38.18 %

Rating:
Buy GILD
up 31.66 %

Rating:
Buy GILD
up 453.22 %

Your Recent Stocks
SymbolLastChange
GILD 106.76 down  -1.13 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy